#1 Clinical Trials Search in Europe

Camizestrant

Camizestrant, also known as AZD9833, is an experimental drug being studied in clinical trials for the treatment of breast cancer. This article summarizes key information about ongoing clinical trials evaluating Camizestrant’s safety, effectiveness, and potential use in combination with other cancer therapies.

Table of Contents

What is Camizestrant?

Camizestrant, also known by its research code AZD9833, is a new drug being developed to treat certain types of breast cancer[1]. It belongs to a class of medications called Selective Estrogen Receptor Degraders (SERDs). These drugs work by targeting and breaking down estrogen receptors in cancer cells, which can help slow or stop the growth of hormone-sensitive breast cancers[2].

Camizestrant is taken orally, which means it’s a pill you can swallow, making it more convenient than some other cancer treatments that require injections or hospital visits[3]. It’s currently being studied in clinical trials to determine its effectiveness and safety.

How Does Camizestrant Work?

Camizestrant works by targeting estrogen receptors in breast cancer cells. Many breast cancers rely on estrogen to grow and spread. By breaking down these receptors, Camizestrant can potentially stop or slow the growth of these cancer cells[2].

This drug is considered a “next-generation” SERD, which means it’s designed to be more effective and potentially have fewer side effects than older drugs in this class. It’s been shown to work in breast cancers with both normal and mutated estrogen receptors, which could make it useful for a wider range of patients[4].

What Conditions Does Camizestrant Treat?

Camizestrant is primarily being studied for the treatment of advanced breast cancer. Specifically, it’s being tested in patients with:

  • Estrogen Receptor-positive (ER+) breast cancer: This means the cancer cells have receptors that attach to the hormone estrogen, which helps them grow[2].
  • HER2-negative (HER2-) breast cancer: This means the cancer cells don’t have high levels of a protein called HER2 on their surface[2].
  • Advanced or metastatic breast cancer: This refers to cancer that has spread beyond the breast to other parts of the body[4].

Camizestrant is being studied both as a standalone treatment and in combination with other cancer drugs, particularly in patients whose cancer has progressed after other treatments[5].

Clinical Trials and Research

Camizestrant is currently being studied in several clinical trials. These trials are designed to:

  • Test how well the drug works compared to existing treatments[2].
  • Determine the best dose of the drug[3].
  • Investigate how the drug interacts with other medications[1].
  • Study the drug’s effects in different patient groups, including those with liver problems[3].
  • Evaluate the drug’s safety and potential side effects[6].

Some trials are also looking at using Camizestrant in combination with other cancer drugs, such as CDK4/6 inhibitors, which are another type of targeted therapy for breast cancer[4].

Potential Side Effects

As Camizestrant is still in clinical trials, the full range of potential side effects is not yet known. However, researchers are carefully monitoring for any adverse effects. Some of the side effects being studied include:

  • Joint pain (arthralgia)[2]
  • Hot flashes[2]
  • Vaginal dryness[2]
  • Changes in liver function[3]

It’s important to note that not all patients will experience these side effects, and the severity can vary from person to person. The clinical trials are designed to carefully monitor and manage any side effects that occur.

Future Prospects

Camizestrant shows promise as a potential new treatment for certain types of breast cancer. If the clinical trials are successful, it could provide a new option for patients, especially those whose cancer has become resistant to other treatments[4].

Researchers are particularly excited about Camizestrant because:

  • It can be taken orally, which is more convenient for patients[3].
  • It may be effective against cancers that have developed resistance to other hormone therapies[4].
  • It’s being studied in combination with other drugs, which could lead to more effective treatment strategies[5].

While the results of these trials are still pending, Camizestrant represents an exciting development in breast cancer research. As always, patients should discuss their treatment options with their healthcare providers to determine the best approach for their individual situation.

Aspect Details
Drug Type Oral selective estrogen receptor degrader (SERD)
Target Cancer ER+/HER2- advanced or early breast cancer
Administration Oral tablets, typically daily dosing
Trial Phases Phase I, II, and III studies ongoing
Combination Studies With CDK4/6 inhibitors, aromatase inhibitors, and other targeted therapies
Key Outcomes Measured Safety, tolerability, pharmacokinetics, tumor response, progression-free survival
Patient Populations Post-menopausal women, various stages of breast cancer
Current Status Experimental, only available through clinical trials

FAQ

  • What type of drug is Camizestrant? Camizestrant is an oral selective estrogen receptor degrader (SERD). It is designed to block and break down estrogen receptors in breast cancer cells, potentially slowing or stopping tumor growth in hormone receptor-positive breast cancers.
  • What types of breast cancer is Camizestrant being studied for? Camizestrant is primarily being studied for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer. Some trials are also evaluating its use in early-stage breast cancer.
  • How is Camizestrant administered? Camizestrant is taken orally in tablet form. The specific dosing schedule varies between clinical trials but is typically taken daily.
  • What are some of the potential side effects of Camizestrant? While specific side effects are still being evaluated in trials, common side effects of SERDs may include hot flashes, joint pain, fatigue, nausea, and bone loss. The ongoing trials are closely monitoring patients for any adverse events.
  • Is Camizestrant approved for use yet? No, Camizestrant is still considered an experimental drug. It is only available through participation in clinical trials at this time. More research is needed to determine its safety and effectiveness before it can be approved for general use.

Ongoing Clinical Trials on Camizestrant

  • A Study of Camizestrant and Ribociclib for Patients with Hormone Receptor-Positive Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Bulgaria Czechia France Germany Hungary +4

  • Study on the Safety of AZD8421 Alone or with Drug Combination for Patients with Advanced Breast Cancer and High-Grade Ovarian Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Hungary Italy Poland Portugal +1

  • Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria France Germany Hungary +6

  • Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia France Germany +7

  • Study of AZD5305 Alone and with Other Cancer Drugs for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Hungary Italy Poland Spain

Glossary

  • SERD: Selective Estrogen Receptor Degrader – a type of drug that blocks and breaks down estrogen receptors in cancer cells
  • ER+: Estrogen Receptor-positive – describes breast cancer cells that have receptors for estrogen, which can promote cancer growth
  • HER2-negative: Refers to breast cancer cells that do not have high levels of a protein called HER2 on their surface
  • Metastatic: Cancer that has spread from its original site to other parts of the body
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized and excreted
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk of cancer coming back
  • CDK4/6 inhibitor: A type of drug that blocks specific proteins involved in cell division, potentially slowing cancer growth
  • Aromatase inhibitor: A type of hormone therapy that lowers estrogen levels in postmenopausal women
  • RECIST: Response Evaluation Criteria In Solid Tumors – a standard way to measure how well a cancer patient responds to treatment
  • Progression-free survival: The length of time during and after treatment that a patient lives with cancer without it worsening

References